Back to Main

Faculty Detail Faculty Entry   
Name G M ANANTHARAMAIAH  
Campus Address BDB 668 Zip 0012
Phone 205-934-1884
E-mail ananth@uab.edu" id="FacultyDetail1EmailAddress"><a href="mailto:ananth@uab.edu">ananth@uab.edu</a>
URL
 
 

Department Affiliations(s)
Appointment Type Department Division Rank
Center  Center for Aging  Center for Aging Professor
Center  Center for AIDS Research  Center for AIDS Research Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor
Center  Medicine  Comprehensive Diabetes Ctr Professor
Center  Medicine  Med - Cardiovascular Disease Professor
Primary  Medicine  Med-Gerontology/Geriatrics/Palliative Care Professor
Secondary  Biochemistry & Molecular Genetics  Biochemistry & Molecular Genetics Associate Professor

Biographical Sketch 
Dr. Anantharamaiah joined UAB in 1982 and is a Professor in the Department of Medicine. His research is supported by grants from NIH.

Society Memberships
Organization Name Position Held Org Link
No records
 

Research/Clinical Interest
Title
Apolipoproteins, Amphipathic Helices and Atherosclerosis
Description
Two mechanisms have been proposed for the progression of atherosclerosis: 1) the cholesterol theory, increased plasma cholesterol levels increased the risk for atherosclerosis 2) injury and endothelial surface perturbation is the major cause of atherosclerosis, which is inhibited by the presence of high levels of good cholesterol (HDL). It has been shown that both apo E (the protein component of very low-density lipoproteins (VLDL) and apolipoprotein A-I (the major protein component of HDL) are antiatherogenic, but by two distinctly different mechanisms. Using the common structural motif present for the lipid associating domains in apolipoproteins, the amphipathic helix, we have been able to design peptide mimics for 1) the rapid removal of atherogenic lipoproteins from circulation in vivo, and 2) inhibit atherosclerosis in atherosclerosis sensitive mice without changing plasma cholesterol profile. Using cell culture studies, we have determined that the peptides that reduce plasma cholesterol levels do so by enhancing their removal by the proteoglycan-mediated pathway. Cell culture studies have also shown that the peptides that inhibit atherosclerosis without altering plasma cholesterol levels do so by “removing the seeding molecules” from atherogenic lipoproteins. The laboratory is now in the process of producing transgenic mice expressing these two types of molecules and determining the exact mechanism(s) of atherosclerotic plaque formation and avenues to inhibit this (these) process(es).

Postdoc Positions Available
Date Posted Position Title
No records
 

Selected Publications 
Publication PUBMEDID
No records
 

Keywords

© 2003 University of Alabama School of Medicine. Copyright Information. UAB Disclaimer.
Contact the MEIS Help Desk if you experience problems with this site.